SPARCL1 and thyroid gland carcinoma: Contrarily, SPARCL1 was decreased in breast invasive carcinoma (BRCA), bladder urothelial carcinoma (BLCA), colon adenocarcinoma (COAD), head and neck squamous cell carcinoma (HNSC), kidney renal papillary cell carcinoma (KIRP), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), prostate adenocarcinoma (PRAD), rectum adenocarcinoma (READ), thyroid carcinoma (THCA), uterine corpus endometrial carcinoma (UCEC) (p < 0.001), stomach adenocarcinoma (STAD), and cervical endocervical cancer (CESC) (p < 0.01).